ETHICAL GUIDELINES AND STUDY DESIGN FOR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY

Authors

  • Ranjit Prasad Swain Dept. of Pharmaceutical Technology, Maharajah's College of Pharmacy
  • Pendela Shilpa Dept. of Pharmaceutical Technology, Maharajah's College of Pharmacy
  • Satyajit Panda

Abstract

Unusual growth in pharma industry has provoked regulatory agencies to establish regulations regarding bioavailability (BA) and bioequivalence
(BE) studies. The BA and BE testing are essential in drug development process, provides the information regarding the kinetics (area under the curve
[AUC], C
max
, T
max
, λ
z
, t
½
, AUC
0→Tss,
C
maxss
, C
minss
, C
avgss
, T
) of single and multiple dose studies and the comparison of medicinal products. Indian Council
of Medical Research (ICMR), Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Indian National Science
Academy (INSA), Institutional Animal Care and Use Committee Guidebook (IACUC), National Institutes of Health, Food and Drug Administration,
World Health Organization (WHO) provides the informations for strengthening the ethical guidelines for using humans and animals in clinical trials
globally. Experimental design will help for better selection of models, number of subjects/animals, study conditions, randomizations, selection of
control groups. Statistical evaluation parameters like Analysis of Variance help for the better interpretation of the data. The present study was aimed
to study the need for BA and BE studies, ethical guidelines, experimental designs, pharmacokinetic endpoints, and their statistical evaluations.
maxss
Keywords: Ethical guidelines, Study design, Bioavailability, Bioequivalence.

Downloads

Download data is not yet available.

References

Johnson SB. Bioavailability and bioequivalence testing. In:

Remington’s G, editors. The Science and Practice of Pharmacy. USA:

Pharmaceutical Press; 2013. p. 349-59.

Hedaya MA. Basic Pharmacokinetics. Special Indian edition.

New York: CRC Press; 2010. p. 69.

Available from: http://www.accessdata.fda.gov/scripts/cder/ob. [Last

accessed on 2015 Jul 28].

and AUC

max

-t

Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/

cfcfr/CFRSearch.cfm?fr=320.25. [Last accessed on 2015 Jul 15].

Available from: http://www.fda.gov/Drugs/

DevelopmentApprovalProcess/ucm079068.htm. [Last accessed on

Jul 03].

Malik V. Law Relating to Drugs and Cosmetics. 23

ed. Lucknow: EBC

Publishers; 2013. p. 1235.

rd

Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. 4

ed.

Hyderabad: Pharma Med Press; 1991. p. 159.

Shargel L, Wu - Pong S, Yu A. Applied Biopharmaceutics and

Pharmacokinetics. 6

ed. Singapore: McGrew-Hill Companies; 2012.

p. 405.

th

Tandon V. Bioavailability and bioequivalence. In: Schoenwald R,

editors. Pharmacokinetics in Drug Discovery and Development.

New York: CRC Press; 2002. p. 97-100.

Available from: http://www.cdsco.nic.in/html/be%20guidelines%20

draft%20ver10%20march%2016,%2005. [Last accessed on

May 24].

Sanmukhani J, Tripathi CB. Ethics in clinical research: The Indian

perspective. Indian J Pharm Sci 2011;73(2):125-30.

Ethical Guidelines for Biomedical Research on Human Subjects.

New Delhi: Indian Council of Medical Research; 2006.

Available from: http://www.wma.net/en/30publications/10policies/b3/

index.html. [Last accessed on 2015 Jul 23].

Available from: http://www.infochangeindia.org/20051112276/Health/

Features/Some-questionable-drug-trials.html. [Last accessed on

May 25].

Available from: http://www.cdsco.nic.in/writereaddata/3

%20

Technical%20%20Committee%20Minutes%2029.04.2013.pdf. [Last

accessed on 2015 Jul 25].

Available from: http://www.icmr.nic.in/bioethics/final_cpcsea.pdf.

[Last accessed on 2015 Jul 25].

Available from: http://www.icmr.nic.in/bioethics/INSA_Guidelines.

pdf. [Last accessed on 2015 Aug 02].

Available from: http://www.grants.nih.gov/grants/olaw/guidebook.pdf.

[Last accessed on 2015 Jul 25].

Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/

cfcfr/CFRSearch.cfm?CFRPart=50. [Last accessed on 2015 Aug 01].

Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/

RunningClinicalTrials/ucm118296.htm. [Last accessed on

Aug 01].

Available from: http://www.fda.gov/downloads/drugs/

guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf.

[Last accessed on 2015 Aug 01].

Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/

cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&

subpartNode=21:5.0.1.1.4.9. [Last accessed on 2015 Aug 01].

Available from: http://www.cioms.ch/publications/layout_guide2002.

pdf. [Last accessed on 2015 Aug 01].

Johnson PD, Besselsen DG. Practical aspects of experimental design in

animal research. ILAR J 2002;43(4):202-6.

Festing MF, Altman DG. Guidelines for the design and statistical analysis

of experiments using laboratory animals. ILAR J 2002;43(4):244-58.

Fagundes DJ, Taha MO. Modelo animal de doença: Critérios de escolha

e espécies de animais de uso corrente. Acta Cir Bras 2004;19:59-65.

Davidson MK, Lindsey JR, Davis JK. Requirements and selection of an

animal model. Isr J Med Sci 1987;23(6):551-5.

Dell RB, Holleran S, Ramakrishnan R. Sample size determination.

ILAR J 2002;43:207-13.

de Aguilar-Nascimento JE. Fundamental steps in experimental design

for animal studies. Acta Cir Bras 2005;20(1):2-8.

Altman DG, Doré CJ. Randomisation and baseline comparisons in

clinical trials. Lancet 1990;335(8682):149-53.

Gupta SC. Fundamentals of Statistics. 7

ed. Mumbai: Himalaya

Publishing House; 2012. p. 12.2, 13.1, 15.5, 15.18.

th

Harrington M, editor. The Design of Experiments in Neuroscience.

ed. New Delhi: SAGE Publications; 2011. p.88.

Qui Y, Chen Y, Zhang GG, Liu L, Porter W, editors. Developing Solid

nd

Oral Dosage Forms: Pharmaceutical Theory and Practice. 1

ed. USA:

Academic Press; 2009. p. 352.

Malik V. Law Relating to Drugs and Cosmetics. 23

Publishers; 2013. p. 1241-58.

rd

st

th

rd

ed. Lucknow: EBC

Available from: http://www.ich.org/fileadmin/Public_Web_Site/

ABOUT_ICH/Organisation/GCC/Topics_under_Harmonisation/

Bioequivalence.pdf. [Last accessed on 2015 Jul 26].

Hedaya MA. Basic Pharmacokinetics. Special Indian edition.

New York: CRC Press; 2010. p. 80.

Asian J Pharm Clin Res, Vol 8, Issue 6, 2015, 28-33

Swain et al.

Tamboli AM, Todkar P, Zope P, Sayyad FJ. An overview on

bioequivalence: Regulatory consideration for generic drug products.

J Bioequiv Availab 2010;2(4):86-92.

Available from: http://www.clindesc.com/Guidelines_online/3%20

Clinical/3.1%20General/3_1_2.pdf. [Last accessed on 2015 Jul 24].

Available from: http://www.bebac.at/lectures/2-1-3-BABE.pdf. [Last

accessed on 2015 Jul 01].

Available from: https://www.law.cornell.edu/cfr/text/21/320.27. [Last

accessed on 2015 Jul 06].

Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/

cfcfr/CFRSearch.cfm?fr=320.27. [Last accessed on 2015 Jul 08].

Grizzle JE. The two-period change-over design and its use in clinical

trials. Biometrics 1965;21():467-80.

Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin

Pharmacol 1979;8(1):7-20.

De Muth JE. Basic Statistics and Pharmaceutical Statistical

Applications. 3

ed. New York: CRC Press; 2014. p. 615, 617, 619.

Hedaya MA. Basic Pharmacokinetics. Special Indian edition.

rd

New York: CRC Press; 2010. p. 74.

Available from: http://www.fda.gov/downloads/drugs/guidance

compliance regulatory information/guidances/ucm073115.pdf. [Last

accessedon 2015 Jul 25].

Bolton S, Bon C. Pharmaceutical Statistics: Practical and Clinical

Applications. 5

ed. New York: Informa Health Care; 2010. p. 623.

Hoffman W, Lee C, Chiang A, Guo K, Ness D. Some statistical

th

considerations in non- clinical safety assessment. In: Dmitrienko A,

Chuang-Stein C, D’Agostino R, editors. Pharmaceutical Statistics

Using SAS: A Practical Guide. USA: SAS Institute; 2007. p. 98-102.

Available from: http://www.fda.gov/downloads/Drugs/./Guidances/

ucm070244.pdf. [Last accessed on 2015 Jul 28].

Niazi SK. Handbook of Bioequivalence Testing. 2

ed. New York:

CRC Press; 2015. p. 410-2.

nd

Available from: http://www.fda.gov/downloads/drugs/

guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf.

[Last accessed on 2015 Jul 28].

Notari RE. Biopharmaceutics and Clinical Pharmacokinetics: An

Introduction. 4

ed. New York: Marcel Dekker; 2010. p. 46-55, 90-99.

Gibaldi M, Perrier D. Pharmacokinetics. 2

th

ed. New York: Informa

Health Care; 2009. p. 145-88.

nd

Available from: http://www.ich.org/fileadmin/Public_Web_Site/

ABOUT_ICH/Organisation/SADC/Guideline_on_Bioavailability_

and_Bioequivalance.pdf. [Last accessed on 2015 Jul 28].

Shaik M, Thirunagari BL, Sathe A. The basic regulatory considerations

and prospects for conducting bioavailability/bioequivalence (BA/BE)

studies – An overview. Comp Eff Res 2011;2011:1-25.

Rani S, Pargal A. Bioequivalence: An overview of statistical concepts.

Indian J Pharmacol 2004;36(4):209-16.

Galgatte UC, Jamdade VR, Aute PP, Chaudhari PD. Study on requirements

of bioequivalence for registration of pharmaceutical products in USA,

Europe and Canada. Saudi Pharm J 2014;22:391-402.

Published

01-11-2015

How to Cite

Swain, R. P., P. Shilpa, and S. Panda. “ETHICAL GUIDELINES AND STUDY DESIGN FOR BIOAVAILABILITY AND BIOEQUIVALENCE STUDY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 6, Nov. 2015, pp. 28-33, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/8330.

Issue

Section

Review Article(s)